TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24321804
Drug: Salmeterol-fluticasone (SFC)
Normalized name: FLUTICASONE/SALMETEROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol-fluticasone (SFC) 50/500 μg twice daily
Study: 21402550
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) concurrent with tuberculosis treatment for 6 months
Study: 21402550
Drug: Tuberculosis treatment
Normalized name: Hydrazides for tuberculosis treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculosis treatment alone
Study: 2039205
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin (400 mg twice a day)
Study: 2039205
Drug: Parenteral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antibiotics (cefazolin, 1.0 g intravenously every 8 h, or ceftazidime, 2.0 g intravenously every 12 h)
Study: 6753642
Drug: Thiopental, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental, 15 mg/kg
Study: 31257453
Drug: ETN 50
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN 50 mg plus MTX
Study: 27252426
Drug: ETN 25
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN 25 mg plus MTX
Study: 31257453
Drug: Full-/reduced-dose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-/reduced-dose combination therapy (ETN 50 mg or 25 mg plus MTX)
Study: 30996038
Drug: Generalizability (G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generalizability (G) study
Study: 9422404
Drug: Conventional CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CsA (Sandimmune formulation) and azathioprine (AZA)
Study: 7795000
Drug: Multi-faceted treatment
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-faceted treatment program for violent spouses
Study: 28389218
Drug: Walking training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking training (WT), n=22, 15 bouts of 2min of walking interpolated by 2min of upright rest, twice/week for 12 weeks
Study: 28389218
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG), n=20, 30min of stretching exercises, twice/week for 12 weeks
Study: 25591836
Drug: Standard aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard aromatase inhibitors (AI) alone
Study: 18307371
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg, 1000 mg, or 2000 mg every 6 or 8 hours by intravenous infusion
Study: 16566555
Drug: Oxandrolone 10
Normalized name: oxandrolone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 10 mg every 12 hours
Study: 11051370
Drug: 5 mU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mU interferon TIW for 6 months + ribavirin (1000‐1200 mg daily) if HCV‐RNA positive at month 3
Study: 11051370
Drug: 3 mU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mU interferon TIW + ribavirin (1000‐1200 mg daily) for 6 months, increased to 5 mU TIW if HCV‐RNA positive at month 3
Study: 11051370
Drug: 5 mU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mU interferon TIW + ribavirin (1000‐1200 mg daily) for 6 months
Study: 24686046
Drug: Triple Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple Injection (TI)
Study: 24686046
Drug: Single Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Injection (SI)
Study: 19890249
Drug: OATP1B3 polymorphism
Normalized name: ANGELICA POLYMORPHA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: OATP1B3 polymorphism 334T>G/699G>A in patients receiving MMF with tacrolimus or sirolimus
Study: 17373169
Drug: Poly-L-lactic acid
Normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-L-lactic acid (PLLA)
Study: 11896506
Drug: Eprosartan 600
Normalized name: eprosartan 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 600 mg plus HCTZ 12.5 mg OD
Study: 11896506
Drug: Eprosartan 600
Normalized name: eprosartan 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 600 mg OD
Study: 10459115
Drug: Topical 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-fluorouracil (5-FU) applied twice per day for 3 weeks
Study: 10459115
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using topical 5-aminolevulinic acid (5-ALA) and irradiation with a 1200 W metal halogen lamp
Study: 8590511
Drug: Edrophonium 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.125 mg.kg-1
Study: 8590511
Drug: Edrophonium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.25 mg.kg-1
Study: 8590511
Drug: Edrophonium 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.50 mg.kg-1
Study: 2270599
Drug: Functional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional therapy with a free way space of greater than or equal to 1.0 mm and cuspid protected guidance
Study: 2270599
Drug: Functional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional therapy
Study: 22075171
Drug: Control hepatitis
Normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control hepatitis A vaccine
Study: 31324360
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy with candesartan
Study: 31324360
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy without candesartan
Study: 23524061
Drug: Exploration phase
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exploration phase (without trauma-focused treatment)
Study: 19263337
Drug: 5 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg/d of nonionic iron polymaltose complex + 25 IU vitamin E (as dl‐alpha‐tocopherol acetate) from 2 weeks of age
Study: 17718920
Drug: Gel-pads
Normalized name: Medicated Pad
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-pads
Study: 11509799
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of diabetes mellitus, older age, increased number of prescribed antihypertensive medications, lower hematocrit, absence of arrhythmias
Study: 11509799
Drug: Younger age,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Younger age, increased number of prescribed antihypertensive medications, absence of arrhythmias
Study: 3257913
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of leucovorin calcium (25 mg)
Study: 3257913
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of leucovorin calcium (25 mg)
Study: 3257913
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of leucovorin calcium (25 mg)
Study: 3257913
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intramuscular administration
Study: 3257913
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three treatments (Intravenous, Intramuscular, Oral)
Study: 23564914
Drug: Intraduodenal glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal glutamine (7.5 or 15 g)
Study: 19741062
Drug: rt‐PA 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA 50 mg/2 h
Study: 19741062
Drug: rt‐PA 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA 100 mg/2 h
Study: 15897822
Drug: Combined manipulative
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined manipulative treatment, stabilizing exercises, and physician consultation
Study: 8522469
Drug: Fluconazole administered
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole administered via feeding tube with concomitant enteral feeds
Study: 8522469
Drug: Fluconazole administered
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole administered as intravenous infusion over 1 h
Study: 2008781
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (received feedback on prescription errors)
Study: 26902950
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 1-month formulation (PP1M)
Study: 21048170
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g tranexamic acid in 100 mL normal saline solution
Study: 21048170
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g tranexamic acid in 100 mL normal saline solution
Study: 17403630
Drug: Preoperative RT-CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative RT-CT (radiotherapy 45 Gy on posterior pelvis + 5-fluorouracil 300 mg/m2/day for 5 days weekly during RT)
Study: 14644719
Drug: Bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03% once daily (n = 90)
Study: 14644719
Drug: Combined timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined timolol 0.5% and dorzolamide 2% twice daily (n = 87)
Study: 29506580
Drug: Starting antiplatelet
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting antiplatelet drugs
Study: 29506580
Drug: Avoiding antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoiding antiplatelet drugs
Study: 24678807
Drug: Arotinolol combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arotinolol combined with nifedipine (30 mg/d nifedipine + 20 mg/d arotinolol)
Study: 24678807
Drug: Arotinolol combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arotinolol combined with amlodipine (5 mg/d amlodipine + 20 mg/d arotinolol)
Study: 24678807
Drug: Arotinolol combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arotinolol combined with felodipine (5 mg/d felodipine + 20 mg/d arotinolol)
Study: 21798784
Drug: Pharmaceutical intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical intervention with a pharmacist explaining prescribed drugs and providing a personalized medication timetable
Study: 21798784
Drug: Pharmaceutical intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical intervention with a pharmacist
Study: 10081699
Drug: Luteinizing hormone-releasing
Normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone analogue (LH-RHa) started the first day of radiotherapy and administered every 4 weeks over 3 years
Study: 10081699
Drug: Luteinizing hormone-releasing
Normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone analogue (LH-RHa) initiated in the last week of radiation therapy and continued until relapse
Study: 10081699
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal therapy with LH-RHa during and after radiation
Study: 8608360
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin therapy
Study: 2200187
Drug: Heparin 5000
Normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5000 IU + 0.5 mg DHE (HDHE) three times a day
Study: 2200187
Drug: Acetyl‐salicylic‐acid (ASA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl‐salicylic‐acid (ASA) 0.5 g + dihydroergotamin (DHE) 2.5 mg three times a day
Study: 7082024
Drug: 5% crude
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% crude coal tar in an absorbent ointment base (Aquaphor)
Study: 7082024
Drug: Absorbent ointment
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbent ointment base alone
Study: 12028324
Drug: Frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan 2.5 mg
Study: 15147247
Drug: Frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan 2.5 mg and Placebo
Study: 12352234
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg three times daily for seven days
Study: 9839847
Drug: C: 25
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C: 25 g creatine monohydrate/day, 5 days
Study: 9839847
Drug: CC: 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC: 25 g creatine monohydrate/day, 5 days plus 5 g/h during exercise
Study: 8301790
Drug: 22-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22-mg nicotine patch therapy with intensive group counseling for 8 weeks (Study 1)
Study: 8301790
Drug: 22-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22-mg nicotine patch therapy for 4 weeks followed by 11-mg nicotine patch therapy for 2 weeks with brief individual counseling (Study 2)
Study: 8301790
Drug: 22-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22-mg nicotine patch therapy
Study: 7897117
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA)
Study: 19921357
Drug: Flurbiprofen 1
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 1 mg kg(‐1) before surgery
Study: 19921357
Drug: Placebo (lipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lipid emulsion 0.1 ml kg(‐1)) before surgery
Study: 17010568
Drug: Cholestyramine (CSM)
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholestyramine (CSM) therapy for 2 weeks
Study: 17010568
Drug: Cholestyramine (CSM)
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholestyramine (CSM) therapy reinstated for 2 weeks
Study: 17010568
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy for 2 weeks
Study: 17010568
Drug: Cholestyramine (CSM)
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholestyramine (CSM) therapy after placebo
Study: 15516022
Drug: Single-dose CF101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose CF101 (1, 5, or 10 mg)
Study: 15516022
Drug: Multiple-dose CF101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose CF101 (2, 3, 4, or 5 mg, 12-hourly for 7 days)
Study: 15516022
Drug: Single-dose CF101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose CF101 (5 mg)
Study: 15516022
Drug: First multiple-dose
Normalized name: allantoin / benzalkonium chloride Topical Foam [Hands First 4 in 1]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First multiple-dose CF101 (5 mg)
Study: 15516022
Drug: After 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 7 days of multiple dosing
Study: 15516022
Drug: Leucocytosis after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocytosis after CF101 (5 and 10 mg)
Study: 15689068
Drug: Artesunate (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (3.3 mg/kg on day 1, followed by 1.65 mg/kg for the next four days, total dose = 600 mg)
Study: 15689068
Drug: Artesunate followed
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate followed by primaquine (15 mg for 14 days)
Study: 272945
Drug: L‐asparaginase 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐asparaginase 1,000 mu/kg iv q.d. x 10, vincristine 2.0 mg/m2 iv q.w. x 4 and prednisone 40 mg/m2 p.o.q.d. x 28 days
Study: 27730325
Drug: Conventional dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional dexamethasone nasal spray
Study: 27730325
Drug: Device using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device using pressure and vibration to distribute steroid aerosol endonasally
Study: 25092886
Drug: HRM diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRM diet (300 g/day lean red meat)
Study: 25092886
Drug: HRM+HAMSB diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRM+HAMSB diet (HRM with 40 g/day butyrylated high amylose maize starch)
Study: 22561907
Drug: PSA threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA threshold of 4 ng ml(‐1)
Study: 16780933
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy (OAT)
Study: 17692112
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic therapy (AT)
Study: 17692112
Drug: OAT prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAT prescription in 2004
Study: 26394202
Drug: Vehicle solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle solution (control group)
Study: 15351853
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (6.0 x 10(6) KIU) systemically for both groups
Study: 11110645
Drug: Intranasal (inl)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (inl) immunization with monovalent, live attenuated, cold‐adapted recombinant (CR) or inactivated influenza virus (MIV) vaccine
Study: 11110645
Drug: Combined inl
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined inl (CR or MIV) and im vaccine
Study: 11110645
Drug: Intramuscular (im)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (im) immunization with MIV
Study: 9701860
Drug: Medication information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication information procedure
Study: 8023663
Drug: Midazolam 75
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 75 micrograms.kg-1 followed by continuous infusion of propofol
Study: 8023663
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg.kg-1 bolus followed by infusion
Study: 31003677
Drug: 5% grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% grape seed extract ointment
Study: 31003677
Drug: 2.5% grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% grape seed extract ointment
Study: 24983681
Drug: Expectant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectant treatment
Study: 19262754
Drug: Rabipur(R) rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabipur(R) rabies vaccine
Study: 2468896
Drug: Nifedipine, 10
Normalized name: Nifedipine, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 10 mg p.o.
Study: 28987445
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of IIV4 and PPV23
Study: 22677718
Drug: Pyridostigmine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (60 mg three times a day, increasing to maximum tolerated dose or 120 mg three times a day for 7 days)
Study: 17541211
Drug: ACEI temocapril
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI temocapril (T) 2 mg/day
Study: 17541211
Drug: ARB candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB candesartan (C) 4 mg/day
Study: 17541211
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (T+C)
Study: 17541211
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (C+T)
Study: 17541211
Drug: Nifedipine-CR (N)
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine-CR (N) 20 mg/day
Study: 17541211
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low doses of ACEI and ARB
Study: 2550046
Drug: Isoprenaline (ISO)
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline (ISO) infusion
Study: 2550046
Drug: Isoprenaline (ISO)
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline (ISO) bolus injections
Study: 779587
Drug: Clonidine 0.225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.225 mg daily (mean dosage varied from 0.225 to 0.900 mg)
Study: 779587
Drug: Practolol 200
Normalized name: (±)-practolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol 200 mg daily (mean dosage varied from 200 to 600 mg)
Study: 779587
Drug: Chlorothiazide 25
Normalized name: chlorothiazide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorothiazide 25 mg added to clonidine in 15 cases
Study: 779587
Drug: Chlorothiazide 25
Normalized name: chlorothiazide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorothiazide 25 mg added to practolol in 18 cases